BiotechTube
Home/Candel Therapeutics/Gary Temple
GT

Gary Temple

Chief Development Officer

Candel Therapeutics

Therapeutic Areas

Oncology

Candel Therapeutics Pipeline

DrugIndicationPhase
CAN-2409Non-Small Cell Lung Cancer (NSCLC)Phase 3
CAN-3110Recurrent High-Grade GliomaPhase 1

Leadership Team at Candel Therapeutics

PP
Paul Peter Tak
President and Chief Executive Officer
FG
Francesco G. Marincola
Chief Scientific Officer
JA
Jason Amello
Chief Financial Officer
RM
Ronald Martell
Chairman of the Board
View full Candel Therapeutics profile